Modification by SUMOs (small ubiquitin-related modifiers) is largely transient and considered to alter protein function through altered protein-protein interactions. These modifications are significant regulators of the response to DNA damage in eukaryotic model organisms and SUMOylation affects a large number of proteins in mammalian cells, including several proteins involved in the response to genomic lesions [Golebiowski, Matic, Tatham, Cole, Yin, Nakamura, Cox, Barton, Mann and Hay (2009) [935][936][937][938][939] has revealed the involvement of the SUMO cascade in the BRCA1 (breast-cancer susceptibility gene 1) pathway response after DNA damage. The present review examines roles described for the SUMO pathway in the way mammalian cells respond to genotoxic stress.
DNA damage
DNA lesions can occur through exogenous and endogenous damage. Damage triggers activation of DNA repair or damage-avoidance pathways: a checkpoint response followed by cell-cycle arrest to allow time for the repair, whereas lesion type and cell-cycle stage determine the repair pathway used. These reactions must be initiated by proteins that recognize DNA lesions, followed by the recruitment and activation of proteins that trigger checkpoint signalling and/or directly repair the lesion. When the repair is completed, the machinery needs to be disassembled, the chromatin reassembled, and the response turned off. Protein modification by phosphorylation and ubiquitination is now recognized as part of the response to DNA damage, particularly ds (doublestranded) DNA damage. It now seems that SUMO (small ubiquitin-related modifier) conjugation, long recognized as a transient and therefore potentially highly regulated modification, is employed by higher organisms as part of DNA repair mechanisms requiring precise spatiotemporal control.
The SUMO pathway
Mammals have three ∼100-amino-acid SUMO isoforms able to form isopeptide linkages. Although the primary sequence and external charge differ, these proteins share their three-dimensional structure and pathway architecture with ubiquitin. SUMO isoforms are covalently attached to target proteins through the sequential activity of a single heterodimeric activating (E1) enzyme and the single E2 enzyme UBC9 (ubiquitin-conjugating enzyme 9), and may or may not require the activity of one of several SUMO E3 ligases {of the SP-RING (secretory protein with a RING finger domain) type, PIAS [protein inhibitor of activated STAT (signal transducer and activator of transcription)] 1-4, and the more distantly related Nse2/MMS21 (methylmethane sulfonate 21), RanBP2 (Ran-binding protein 2) at the nuclear pore, Polycomb protein 2 and TOPORS (topoisomerase I binding, arginine/serine-rich), a RING E3 for both SUMO and ubiquitin}. SUMO is processed from its peptide precursor and cleaved or edited on the substrate by one or more of the six SUMO proteases {SENP [SUMO1/ sentrin/SMT3 (suppressor of mif two 3 homologue 1)-specific peptidase 2] 1, 2, 3, 5, 6 and 7}.
Unlike ubiquitin modification, SUMO conjugation frequently, but not always, occurs at the lysine residue within the consensus ψKXE (where ψ is an aliphatic residue and X is any residue). The SUMO-2 and SUMO-3 families (which differ by only three amino acids) contain within their sequence a ψKXE consensus and are therefore able to form poly-SUMO chains, whereas SUMO-1, like the Saccharomyces cerevisiae SUMO, lacks this consensus and is conjugated as a single moiety to substrate proteins. (Schizosaccharomyces pombe has a single SUMO with an N-terminal extension containing lysine residues that enable SUMO-chain extensions [1] .) Specificity of targeting is apparently achieved with relatively few E3s and just one E2. The potential for further regulation is seen in expanded modification and interaction motifs, often encompassing phosphorylation sites. For example, phosphorylation of either the modification site ψKXEXXSP or the serine residue within the acidic region that follows some SIMs (SUMO-interacting motifs; V/IXV/I, V/I) respectively enhances UBC9 or SUMO interaction, increasing specificity of conjugation or interaction. The SLDs (SUMO-like domains) are an intriguing addition to these modules. SLD-containing proteins resemble a constitutively SUMOylated target that is able to bind SUMO pathway components.
Although not yet shown to play a role in the mammalian pathway, SLD-containing proteins include NIP45 (nuclear factor of activated T-cells-interacting protein 45), the human homologue of yeast Rad60/Esc2 (in S. pombe and S. cerevisiae respectively) that play an important role in the yeast response to replicative stress [2, 3] .
Deletion of the single SUMO genes in Caenorhabditis elegans or S. cerevisiae is lethal, as is knockout of Ubc9 in mammalian cells [4] . However, SUMO modification is not always necessary for life. In S. pombe, deletion of pmt3 (its only SUMO homologue) is non-lethal, although loss of the pathway components renders cells sensitive to DNAdamaging agents (reviewed in [5] ). In mammalian systems it is clear that the pathway contains flexibility and overlap. For example, SUMO-1-knockout mice have a minimal phenotype [6] , presumably due to redundancy with SUMO2/3, and knockout of one of the four PIAS E3 ligases in mice produces a subtle phenotype, whereas removal of two is lethal [7] .
Consequences of SUMO modification
The number of mammalian SUMO-conjugation target proteins identified, even before recent proteomic analyses were published, outnumbered those for which a specific consequence of the modification could be identified. Based on a small number of intensively investigated substrates, the view that SUMOylation had an impact on function in a targetspecific way, increasing or decreasing interactions particular to the context of the protein, predominated (reviewed in [8] ). The regulation of the BER (base excision repair) enzyme TDG (thymine DNA glycosylase) illustrates the complexity and exquisite control that SUMO modification and interaction allow even in the regulation of a single DNA repair enzyme (reviewed in [9] ). BER is the principal mode of repair for the replacement of irregular bases. TDG recognizes and removes the aberrant base, leaving an abasic site that is further repaired by downstream enzymes. The rate-limiting step is the release of the TDG from the abasic site. SUMO modification of TDG induces a conformational change in the N-terminal domain that reduces the affinity of the enzyme for DNA. As a result, the less demanding G•U mismatch is processed instead of the G•T mismatch, which requires strong DNA binding for recognition. The modification affects only DNA-bound TDG, and allows the glycosylase to dissociate from the lesion after base release, so that BER can proceed. TDG also interacts non-covalently with SUMO, through two SIMs. This interaction is essential for the activation of associated histone acetyltransferase CBP [CREB (cAMP-response-element-binding protein)-binding protein]/p300 and relocalization of TDG to PML (promyelocytic leukaemia) bodies (nuclear foci containing PML protein). However, when SUMO is conjugated the SIM is occupied, and not free for non-covalent binding of SUMO, thereby blocking interaction with CBP and preventing TDG acetylation in vitro. Consistent with this, the SUMOylationdeficient mutant accumulates in PML bodies. Thus the SUMO pathway regulates both the enzymatic activity and the subcellular location of TDG.
More recently, STUbLs (SUMO-targeted ubiquitin ligases) have been identified in humans [RNF (RING finger protein) 4], S. cerevisiae (Slx5/8) and S. pombe (Rfp1/2) [10] . These reveal a more general consequence of SUMOylation: degradation. STUbLs are RING-domain E3 ubiquitin ligases that contain SIMs. SUMO-conjugated proteins interact with the ubiquitin ligase through its SIMs; they are then ubiquitinated and targeted for degradation to the proteasome. Presumably the specific site of SUMO modification is less important for a STUbL target than for proteins where modification regulates a specific function, but whether poly-SUMOylation is sufficient to identify an RNF4 target is currently unclear. RNF4 targets appear to represent a large proportion of SUMO-2/3 conjugates in mammalian cells since depletion of RNF4, like depletion of SUMO proteases, results in an increase in total cellular SUMO-2/3 conjugates [11] . The degree to which RNF4 is 'mopping up' bystander SUMO targets, conjugated as a consequence of poor specificity of the pathway, and/or is specifically regulating SUMOylated targets, is not yet clear. However, in at least one example, that of arsenic-induced PML poly-SUMOylation and subsequent RNF4-dependent degradation, its activity is clinically relevant [11] [12] [13] . That STUbL targets are degraded, as compared with undergoing altered protein interaction and/or de-SUMOylation, suggests that these particular SUMO conjugates serve a function that the cell seeks to regulate tightly. Indeed, yeast cells lacking Slx8/Rfp accumulate SUMO conjugates and are genomically unstable and hypersensitive to genotoxic stress [14] .
SUMO in the BRCA1 (breast-cancer susceptibility gene 1) pathway
DNA ds breaks occur because of faulty replication and/or insult from exogenous agents such as γ -irradiation. In mammals the process of building the repair complex at damage sites takes place within large protein assemblies, microscopically identifiable as repair foci. It is a phosphorylationand ubiquitin-regulated cascade comprising the sequential recruitment of three E3 ubiquitin ligases. The binding of the MDC1 (mediator of DNA damage checkpoint 1) protein to the phosphorylated tail of histone H2AX (γ H2AX) at sites of DNA breakage recruits the ubiquitin ligase RNF8, which together with the second ubiquitin ligase, RNF168/RIDDLE (radiosensitivity, immunodeficiency, dysmorphic features and learning difficulties), generates ubiquitin chains bound by RAP80 (receptor-associated protein 80)-ABRA1 (Abraxas 1), which in turn recruits the final ubiquitin ligase in the cascade, the breast and ovarian cancer predisposition protein, BRCA1 (reviewed in [10] ).
We [15] and the laboratory of S.P. Jackson [16] have recently shown that the SUMO pathway has at least two points of regulation in the accumulation of the ds repair proteins (Figure 1 ). After DNA damage or replication stress, SUMO pathway components (SUMO isoforms, UBC9, PIAS and MMS21 SUMO ligases) accumulate at sites within the nucleus where DNA damage has occurred. The PIAS1 and PIAS4 SUMO ligases, but not MMS21, are required for complete accretion of repair proteins to the damaged sites. These ligases are not equivalent, with PIAS4 required earlier in the cascade, influencing RNF168 and subsequent RNF168-dependent protein recruitment, and PIAS1 only influencing RAP80 and BRCA1 accumulation. PIAS ligases have previously been implicated in the response to genotoxic stress. Depletion of GEI-17, the single PIAS SUMO E3 orthologue in C. elegans, which is required for embryonic DNA-damage response [17, 18] , results in altered growth and development. Human PIAS4 is essential for DNA-damage-induced NF-κB (nuclear factor κB) activation [19] , whereas in chicken DT40 cells, interaction between SNM1A and PIAS1 is required for inter-strand cross-link DNA repair [20] . Consistent with their role in controlling earlier-arriving repair protein accumulation, depletion of PIAS1 or PIAS4 reduces the mammalian response to ds breaks by both HR (homologous recombination) and NHEJ (non-homologous end-joining) repair [15, 16] .
The SUMO pathway also directly influences BRCA1 activity. BRCA1-dependent ubiquitin conjugates at sites of DNA damage repair have been observed in human [21] , C. elegans [22] and Gallus gallus [23] cells, and appear to be dependent on at least one ubiquitin-Lys 6 -ubiquitin linkage [21, 24, 25] . Although BRCA1 accumulates poorly in PIASdepleted cells, those BRCA1 damage foci that do form lack co-localizing conjugated ubiquitin and fail to accrue Lys 6 -only ubiquitin. BRCA1 is itself modified in a PIAS1-and PIAS4-dependent manner by SUMO-1 and SUMO-2 after treatment with genotoxic agents, and an N-terminal ψKXE consensus within BRCA1 is required both for interaction with SUMO in cells and for BRCA1 ubiquitin ligase activity in cells. Importantly, when the ubiquitin ligase activity of purified SUMO-modified BRCA1-BARD1 (BRCA1-associated RING domain 1) was compared with that of unmodified protein, the modified heterodimer had 10-20-fold more activity, identifying BRCA1 as an SRUbL (SUMOregulated ubiquitin ligase) [15] . The mechanism underlying this activity is not yet clear: many ubiquitin-conjugating enzymes with which BRCA1 is active contain SIM motifs, evoking a model of increased protein-protein interaction, perhaps similar to the ubiquitin-E2 interaction thought to explain the observation of increased BRCA1 ubiquitin ligase activity on autoubiquitination [26, 27] .
BRCA1 and PIAS1 proteins exist in a complex in cells (R. Densham and J.R. Morris, unpublished work). However, whether and how these ligases interact directly with dsDNA damage repair proteins remain to be elucidated. In the yeast PCNA (proliferating-cell nuclear antigen)-Siz/PIAS interaction, the central SP-RING domain (structurally similar to the ubiquitin E3 ligase RING) is thought to interact with UBC9, the C-terminal acidic elements with SUMO and the N-terminal PINIT domain is required for binding to PCNA [28] . PIAS ligases' SAP domains interact with sequence-or structure-specific DNA, and PIAS1/4 require SAP domains to localize to the site of DNA damage [16] . PIAS ligases have other features that are intriguing in the light of their role in protein accumulation in DNA repair: they are regulated by phosphorylation; they have ligase-independent functions often linked to their SUMOtethering function; and they have the capacity to interact with each other to form multicomponent complexes (reviewed in [29] ).
These studies predict that certain early-arriving proteins are likely to be SUMO targets. Indeed, we find that RNF168 is modified by histidine-tagged SUMO isoforms in a PIAS1-and PIAS4-dependent manner (R. Densham and J.R. Morris, unpublished work), and SUMOylation of RAP80 has already been described [30] . How the modification might regulate its accumulation is not yet clear. It is possible, for example, that, like the BRCA1 ubiquitin ligase, the other ubiquitin ligases in the pathway, RNF8 and RNF168, are also SRUbLs.
The considerable involvement of the SUMO pathway in BRCA1-damage response predicts that perturbation of SUMO maturation and deconjugation, or degradation of SUMOylated proteins, would have a dramatic effect on repair and cellular sensitivity to genotoxic agents. Thus it seems likely that one or more of the six human SENPs (reviewed in [31] ) and/or RNF4 may prove valuable tools in the further dissection of the role SUMOylation plays in this pathway.
SUMO in HR
In S-phase and G 2 cell-cycle phases, signalling protein recruitment to sites of DNA damage can progress to HR repair. RAD52 (and in humans also BRCA2) removes the single-stranded binding protein from part-processed dsDNA breaks and replaces it with the RecA recombinase RAD51, forming nucleoprotein filaments that finally catalyse recombination between homologous sequences. Recently, SUMO modification of replicative Rad52 in yeast was found to shield it from proteasomal degradation. RAD51 interacts with SUMO, but this appears unrelated to conjugation [32] , and its relevance is unknown. One possibility is that the RAD51-SUMO interaction is related to the immediately preceding, SUMO-modified Rad52 assembly factor or the subsequent modification of the branch-migration factor RAD54, recently identified as a SUMO-2 target [33] .
The RecQ family of DNA helicases, WRN (Warner's syndrome protein) and BLM (Bloom's syndrome protein) (Rqh1 in S. pombe, and Sgs1 in S. cerevisiae), are also SUMOylation targets [33, 34] . They unwind a variety of structures including DNA displacement loops and four-way (Holliday) junctions formed after RAD51 recombination, and may act as antirecombinases. DNA damage induces the migration of BLM from PML nuclear bodies to DNA repair foci. BLM that cannot be modified by SUMO fails to localize to PML nuclear bodies, and can only partially complement genomic instability phenotypes in Bloom syndrome cells, as assessed by sister-chromatid exchange.
The SUMO ligase MMS21 is thought to regulate RecQ helicase activity and MMS21 also forms part of the SMC5/6 (structural maintenance of chromosomes 5/6) complex, required late in HR at the point of resolving joint DNA molecules (and also in collapsed replication fork restart, and telomere elongation by HR). MMS21 SUMOylates SMC6 and NSE4 and a number of other targets after MMS-induced damage. Similarly, human MMS21 is required for adequate DNA repair after MMS exposure, and in yeast, the E3 ligase dead versions of the enzyme are hypersensitive to MMS and show increased collapsed replication forks (reviewed in [35] ).
SUMO in NHEJ
NHEJ, responsible for rejoining most of the ds breaks in mammalian cells (in G 1 ) is also influenced by SUMO conjugation. The Ku70-Ku80 heterodimer that detects and binds to the ds break is conjugated [33, 36] , as is the subsequently recruited XRCC4 (X-ray repair complementing defective repair in Chinese-hamster cells 4) [33, 37] required for end ligation. Modification of XRCC4 is necessary for its translocation to the nucleus and for radiation resistance [37] .
The SUMO pathway and human disease
Mutation or loss of genes required for the complete response to DNA damage often gives rise to genome instability and cancer predisposition syndromes. What of the genes in the SUMO pathway? SUMOylation has redundancy in some areas (several SUMO isoforms and several, sometimes redundant, ligases, plus frequently redundant modification sites and multiple SENPs), reducing the risk of loss of activity even from multiple hits. Moreover, sometimes protein interactions occur even in the absence of modification, with the attached modifiers strengthening (or reducing) the associations. Thus some SUMO-regulated pathways might 'get by' without the modification. An Achilles heel, if there is one, must be the single conjugating enzyme, UBC9. UBC9 has been reported to be disregulated in a number of tumour types (e.g. breast [38] and head and neck [39] ), and common single-nucleotide polymorphisms in the UBC9 locus are associated with increased breast tumour grade and risk [40, 41] , although the causative variant of this association has not yet been identified.
Similarly, the STUbL RNF4 appears to have little redundancy with an alternative activity, and has the potential to influence multiple pathways. It too has been implicated in several human diseases including cancer (testicular germ cell), and its chromosomal location (4p16.3) is a mutation hotspot [42] . There are some reports of altered SENP expression in tumorigenesis [43] : for example, SENP1 is up-regulated in thyroid oncocytic and prostate tumours [44, 45] , but reduced in a metastatic prostate cell line [46, 47] , and disrupted by constitutional translocations and breakpoints in tumours [48, 49] .
Summary
The SUMO conjugation pathway has been maintained and expanded in higher organisms and is employed as a means of regulating protein interactions in the response to genotoxic stress. Recent findings also highlight the dialogue between modification pathways in the existence of an SRUbL and STUbLs. Other iterations may exist: for example, the de-ubiquitinating enzyme, USP1 (ubiquitinspecific peptidase 1), required for ubiquitin removal from FANCD2/I (Fanconi's anaemia complementation group D2/I), is a SUMO target (as are FANCD2/I) [33] . By analogy with the STUbL phenotype in yeast, it seems likely that a considerable number of SUMOylated proteins making up the mammalian DNA-damage response pathway may be degraded by RNF4 activity. The recent finding that the SUMO pathway plays a role in the BRCA1-damage response [15, 16] , and in DNA replication and further repair pathways [33] , suggests that compounds that block enzymes related to SUMOylation, currently under development, will have clinical as well as academic uses. 
